{
  "id": "56c079b1ef6e394741000022",
  "type": "factoid",
  "question": "Idarucizumab is an antidote of which drug?",
  "ideal_answer": "Idarucizumab is an antidote of Dabigatran. It is used for Dabigatran Reversal.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26069913",
    "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
    "http://www.ncbi.nlm.nih.gov/pubmed/26088576",
    "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
    "http://www.ncbi.nlm.nih.gov/pubmed/26088268"
  ],
  "snippets": [
    {
      "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three novel molecules (idarucizumab, andexanet, and PER977) may provide the most effective and safest way of reversal. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTERPRETATION: These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab for Dabigatran Reversal.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.METHODS: We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ".CONCLUSIONS: Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931"
  ],
  "exact_answer": "dabigatran"
}